NCT02555696

Abraxane in Treatment of Metastatic Breast Cancer

Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 203 (actual)
• Sponsor: Celgene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational project is collecting tolerability, safety and efficacy data with the routine use of Abraxane in the treatment of metastatic breast cancer. Additionally data on the dosage of Abraxane and general data on the disease and the health status of the patient will be collected.

Detailed description

This observational program is aimed at gaining tolerability, safety and efficacy data with the routine use of Abraxane in its labelled indication in metastatic breast cancer. Additionally data on real life dosing in daily clinical routine will be analyzed. A detailed record of the medical history including co-morbidities and pre-treatment regimens will allow analysis of the impact thereof on tolerability, dosage and efficacy. This data might also be supportive for further treatment optimization of Abraxane in Metastatic Breast Cancer (MBC).

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	nab-paclitaxel	nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity

Timeline

• Start date: 2012-05-31
• Primary completion: 2016-02-28
• Completion: 2016-12-31
• First posted: 2015-09-21
• Last updated: 2017-02-23

Locations

13 sites across 1 country: Austria